DAY 1: Thursday, January 21, 2027
Urinary Tract Tumors

Session #1: Non-Muscle Invasive Bladder Cancer (NMIBC)

CO-CHAIRS: SETH LERNER, TODD MORGAN

8:15AM	**Session 1:** Introduction	Co-Chairs
8:20 AM	**Talk 1:** Risk stratification & disease-state treatment framework	Sima Porten
8:28 AM	**Talk 2:** When is Radiation an option for patients with NMIBC	Leslie Ballas
8:36 AM	**Talk 3:** Biomarkers in NMIBC with emphasis on utDNA and ctDNA	Roger Li
8:44 AM	**Debate 1:** Has the Time Come to Move Beyond BCG alone as Primary Therapy for High-Risk NMIBC?	Josh Meeks Todd Morgan
8:56 AM	**Discussion & Q&A**	
9:10 AM	**Debate 2:** Should Combination Intravesical Therapy Replace Single-Agent Intravesical Approaches for BCG-Unresponsive Disease?	Aly-Khan Lalani Seth Lerner
9:22 AM	**Discussion & Q&A**	
9:36 AM	**Panel Discussion & Integrated Q&A - Case based**	Wesley Yip
9:55 AM	**Pre-Voting Question Review**	Meeting Directors

Session #2: Muscle-Invasive Bladder Cancer (MIBC) Perioperative Management

CO-CHAIRS: TOM POWLES, SRIKALA SRIDHAR

10:25 AM	**Session 2:** Introduction	Co-Chairs
10:30 AM	**Talk 1:** Perioperative Therapy in Cisplatin-Ineligible MIBC — EV+P vs. VOLGA	Guru Sonpavde
10:38 AM	**Talk 2:** Perioperative Therapy in Cisplatin-Eligible MIBC — EV+P vs. NIAGARA	Ulka Vaishampayan
10:46 AM	**Debate 1:** Should Bladder Preservation Be Offered to Patients Achieving Clinical Complete Response on Neoadjuvant EV+P?	Jason Efstathiou Dan Petrylak
11:02 AM	**Discussion & Q&A**	
11:12 AM	**Debate 2:** Is Adjuvant Therapy Necessary for Patients with pCR at Cystectomy After Neoadjuvant EV+P?	Daniel Geynisman Michiel Van Der Heijden
11:28 AM	**Discussion & Q&A**	
11:38 AM	**Talk 3:** Integrating ctDNA/MRD Data into Perioperative Decision-Making	Andrea Necchi
11:46 AM	**Panel Discussion & Integrated Q&A**	
12:05 PM	**Pre-Voting Question Review**	Meeting Directors

Session #3: First-Line Urinary Tract Tumors

CO-CHAIRS: ANDREA APOLO, MATTHEW GALSKY

1:25 PM	**Session 3:** Introduction	Co-Chairs
1:30 PM	**Talk 1:** Frontline Therapy After Progression on Perioperative EV+P	Andre Fay
1:38 PM	**Debate 1:** Should EV+P Rechallenge Be Considered After Progression on Perioperative EV+P?	Yasser Ged Katy Beckermann
1:54 PM	**Discussion & Q&A**	
2:04 PM	**Talk 2:** Optimizing EV+P in the Frontline Metastatic Setting — Dosing, Toxicity, and Duration	Abhishek Tripathi
2:12 PM	**Talk 3:** Biomarker-Directed Frontline Strategy — The Role of HER2	Benjamin Maughan
2:20 PM	**Debate 2:** Should HER2-Directed Therapy Replace EV+P as Frontline Therapy in HER2-Positive Metastatic Disease?	Stephanie Berg Yousef Zakharia
2:36 PM	**Discussion & Q&A**	
2:46 PM	**Panel Discussion & Integrated Q&A**	
3:05 PM	**Pre-Voting Question Review**	Meeting Directors

Session #4: Later-Line Urinary Tract Tumors

CO-CHAIRS: JOAQUIM BELLMUNT, MATTHEW MILOWSKY

3:35 PM	**Session 4:** Introduction	Co-Chairs
3:40 PM	**Debate 1:** In a Biomarker-Positive Patient Progressing on Frontline EV+P, Should Biomarker-Directed Therapy Take Precedence Over Platinum-Based Chemotherapy?	David Aggen Jacqueline Brown
3:56 PM	**Discussion & Q&A**	
4:06 PM	**Talk 1:** Integrating FGFR3, HER2, and Cisplatin Eligibility into Later-Line Treatment Selection	Shilpa Gupta
4:14 PM	**Debate 2:** In Sequencing Multiple ADCs, What Should Guide the Choice? Target-Driven vs. Payload Driven	Vadim Koshkin Alexandra Drakaki
4:30 PM	**Discussion & Q&A**	
4:40 PM	**Talk 2:** Treatment Approach for Variant Histology in Advanced Disease	Daniel George
4:48 PM	**Talk 3:** Novel Drugs and Emerging Therapeutic Targets	Gopakumar Iyer
4:56 PM	**Panel Discussion & Integrated Q&A**	
5:15 PM	**Pre-Voting Question Review**	Meeting Directors

DAY 2: Friday, January 22, 2027
Special Session & Renal Cell Carcinoma

Session #5: Integration of ADCs, T-Cell Engagers, and Theranostics across Prostate, Kidney & Urinary Tract Tumors (Special Session)

CO-CHAIRS: MICHAEL MORRIS, NEERAJ AGARWAL

8:15 AM	**Session 5:** Introduction	Co-Chairs
8:20 AM	**Talk 1:** Antibody-Drug Conjugates (ADCs) in GU Malignancies	Scott Tagawa
8:28 AM	**Discussion & Q&A**	
8:40 AM	**Talk 2:** T-Cell Engagers (TCEs) in GU Malignancies	Tanya Dorff
8:48 AM	**Discussion & Q&A**	
9:00 AM	**Talk 3:** Radiopharmaceutical Therapy in GU Malignancies	Ken Herrmann
9:08 AM	**Discussion & Q&A**	
9:20 AM	**Talk 4:** Integration of PET Imaging Diagnostics	Jeremie Calais
9:28 AM	**Discussion & Q&A**	
9:40 AM	**Panel Discussion & Integrated Q&A**	
9:55 AM	**Pre-Voting Question Review**	Meeting Directors

Session #6: Localized RCC

CO-CHAIRS: BRADLEY MCGREGOR, ERIC SINGER

10:25 AM	**Session 6:** Introduction	Co-Chairs
10:30 AM	**Talk 1:** Risk Stratification in Localized RCC — Beyond TNM	Brian Shuch
10:38 AM	**Talk 2:** Histology and Biology of Localized RCC	Michelle Hirsch
10:46 AM	**Discussion & Q&A**	
10:58 AM	**Debate:** Should Belzutifan + Pembrolizumab Replace Single-Agent Pembrolizumab as Preferred Adjuvant Therapy?	James Larkin Naomi Haas
11:14 AM	**Discussion & Q&A**	
11:26 AM	**Talk 3:** Emerging Tools for Risk Refinement	Thai Ho
11:34 AM	**Talk 4:** The Evolving Role of Neoadjuvant Therapy in Localized RCC	Axel Bex
11:42 AM	**Panel Discussion & Integrated Q&A**	
12:05 PM	**Pre-Voting Question Review**	Meeting Directors

Session #7: First-Line RCC

CO-CHAIRS: ROBERT MOTZER, MICHAEL ATKINS

1:25 PM	**Session 7:** Introduction	Co-Chairs
1:30 PM	**Talk 1:** Choice of First-Line Therapy in a Changing Treatment Landscape	Eric Jonasch
1:38 PM	**Debate 1:** Debate: Non-Clear Cell RCC; Are IO Doublets the Standard of Care?	Maria Carlo Pedro Barata
1:52 PM	**Discussion & Q&A**	
2:02 PM	**Talk 2:** Biomarkers in Directing First-Line Therapy: What is their Role? Tissue Based vs. Serum Based	David Braun Vincent Xu
2:16 PM	**Debate 2:** Is there a Role for Studying Triplets Further in the Frontline Setting?	Brian Rini Tian Zhang
2:30 PM	**Discussion & Q&A**	
2:40 PM	**Talk 3:** Treatment Choices of Systemic Therapy for Specific Clinical Settings Based on Sites of Disease	Asim Bilen
2:48 PM	**Panel Discussion & Integrated Q&A**	
3:05 PM	**Pre-Voting Question Review**	Meeting Directors

Session #8: Later-Line RCC

CO-CHAIRS: MARTIN VOSS, CRISTINA SUAREZ

3:35 PM	**Session 8:** Introduction	Co-Chairs
3:40 PM	**Debate:** Should Later-Line Therapy be a Doublet or Single-Agent Therapy?	David McDermott Laurence Albiges
3:56 PM	**Discussion & Q&A**	
4:10 PM	**Talk 1:** AE Management Strategies for HIF-2α Inhibitors	Manuela Schmidinger
4:18 PM	**Talk 2:** Is there a Role for Immunotherapy in Later-Line RCC?	Monty Pal
4:26 PM	**Discussion & Q&A**	
4:36 PM	**Talk 3:** Integration of MDT	Chad Tang
4:44 PM	**Talk 4:** Novel Treatments & Emerging Therapeutic Targets in RCC	Ritesh Kotecha
4:52 PM	**Panel Discussion & Integrated Q&A**	
5:15 PM	**Pre-Voting Question Review**	Meeting Directors